| For: | Peverelle M, Ng J, Peverelle J, Hirsch RD, Testro A. Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. World J Gastroenterol 2023; 29(47): 6165-6167 [PMID: 38186682 DOI: 10.3748/wjg.v29.i47.6165] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i47/6165.htm |
| Number | Citing Articles |
| 1 |
Rupayan Kundu, Lyudmila Shtoff. Semaglutide‐Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury. Clinical Case Reports 2025; 13(8) doi: 10.1002/ccr3.70783
|
| 2 |
Jordan S. Woodard, Jena Velji-Ibrahim, Jay Alden, Gary A. Abrams, Yoshifumi Nakayama. VCTE Overestimates Liver Fibrosis due to Abdominal–Truncal Adiposity and Not Hepatic Steatosis: A Case Report. Case Reports in Gastrointestinal Medicine 2024; 2024(1) doi: 10.1155/2024/7938701
|
| 3 |
Brian J. Wentworth. Metabolic dysfunction-associated steatotic liver disease throughout the liver transplant cycle: a comprehensive review. Metabolism and Target Organ Damage 2024; 4(4) doi: 10.20517/mtod.2024.45
|
| 4 |
Francesco Saverio Papadia, Marco Miggino, Alessandro Gambella, Federica Grillo, Enzo Andorno. De novo acute liver failure requiring urgent liver transplantation after sleeve gastrectomy: A case report. Surgery Case Reports 2026; 8 doi: 10.1016/j.sycrs.2026.100201
|
| 5 |
Francisco Mercado, Michaela Kop, Michelle Trinh. GLP-1 receptor agonists in delirium and encephalopathies: a neuroprotective scoping review. Discover Medicine 2025; 2(1) doi: 10.1007/s44337-025-00428-0
|
| 6 |
Yaowei Bai, Jiacheng Liu, Yu Lei, Bo Sun, Wenlong Wu, Xiatong Bai, Yang Su, Wei Tan, Xuefeng Kan, Chuansheng Zheng. Recompensation after transjugular intrahepatic portosystemic shunt reduces mortality risk: A long-term follow-up study. European Journal of Radiology 2025; 190 doi: 10.1016/j.ejrad.2025.112212
|
| 7 |
Devaraj Ezhilarasan. Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?. Journal of Gastroenterology and Hepatology 2025; 40(9) doi: 10.1111/jgh.17037
|
| 8 |
Ian Strohbehn, Anant D. Bhave, Joshua Kallen, Geoffrey M. Scriver, Christopher S. Morris, Bill S. Majdalany. GLP-1 Receptor Agonists and Transjugular Intrahepatic Portosystemic Shunt: A Word of Caution. Journal of Vascular and Interventional Radiology 2026; 37(3) doi: 10.1016/j.jvir.2025.107961
|
| 9 |
|
| 10 |
Eda Kaya, Wing-Kin Syn, Paul Manka. Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot. Current Opinion in Gastroenterology 2025; 41(3) doi: 10.1097/MOG.0000000000001083
|
| 11 |
Matthew Peverelle, Mzamo Mbelle, Deepak Joshi. New Names, New Drugs, Better Outcomes in Steatotic Liver Disease. British Journal of Hospital Medicine 2025; 86(8) doi: 10.12968/hmed.2024.0655
|
| 12 |
Haoze Yang, Xuyao Zhang, Dan Zhou, Jing Zou, Lei Xu, Meihan Chen, Siyu Zhao, Jiaxuan Dai, Xiaoming Wang, Xi Du, Jia Liu, Yuhong Huang, Guixiang Pan. Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology. Biochemical Pharmacology 2026; 252 doi: 10.1016/j.bcp.2026.118225
|